Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-370-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110215.22.2-370-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"It is not every day that we have the opportunity to discuss a subject as important as the EU patent, which is the subject of Mr Lehne’s recommendation. I am therefore very pleased to be given the chance to contribute to this debate. Firstly, it should be noted that we are currently at a very early stage of the enhanced cooperation procedure. All that the European Parliament’s recommendation will do is to enable the Council to agree officially to measures being taken. Everything is therefore still possible, or, to be more specific, amendments can be made to the European Commission’s proposals for regulations. Without going into details as regards the proposals for regulations on the patent itself or the language regime, I would like to say that while implementing this great European project, we must bear in mind the interests of all European entrepreneurs, or, in other words, both those who patent inventions and those who are interested in easy access to technical information regarding such inventions. I am thinking here of the manufacturers of generic medicines, for example.
Since I am a staunch supporter of the European patent and, at the same time, a representative of Poland, a country which today is unfortunately more a patent ‘recipient’ than a patent ‘donor’, I will endeavour to ensure that the scope of the debate on the patent is as broad as possible, and that it pays heed to everyone’s opinions, in particular, those of small and medium-sized enterprises, which are essential for an innovative European economy."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples